Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia

NCT00095381 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, T-Cell

Interventions

DRUG: forodesine hydrochloride (BCX-1777)

Sponsor

BioCryst Pharmaceuticals